Download PDF
Aktuelle Neurologie 2012; 39(07): 374-382
DOI: 10.1055/s-0032-1305185
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Progressive multifokale Leukenzephalopathie und moderne MS-Therapie – Diagnostik und Therapie

Progressive Multifocal Leukoencephalopathy and Modern MS Therapy – Diagnostics and Therapy
K. Hellwig
,
N. Trampe
,
C. Lukas
,
R. Gold
Further Information

Publication History

Publication Date:
06 September 2012 (online)

Also available at
    Permissions and Reprints

Lernziele

Nach der Lektüre dieses Artikels soll der Leser

  • einen Überblick über die häufigsten Erkrankungen und Therapien haben, die zu einer PML führen können,

  • die wichtigsten Symptome und Schritte zur Diagnosestellung sowie

  • Möglichkeiten zur PML-Risikostratifizierung unter Natalizumab kennen.

 

  • Literatur

  • 1 Bofill-Mas S, Girones R. Role of the environment in the transmission of JC virus. J Neurovirol 2003; 9 (Suppl. 01) 54-58
    PubMedGoogle Scholar
  • 2 Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303
    CrossrefPubMedGoogle Scholar
  • 3 Kedar S, Berger JR. The changing landscape of progressive multifocal leukoencephalopathy. Curr Infect Dis Rep 2011; 13: 380-386
    CrossrefPubMedGoogle Scholar
  • 4 D'Souza A, Wilson J, Mukherjee S et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010; 10: E1-9
    PubMedGoogle Scholar
  • 5 Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824
    CrossrefPubMedGoogle Scholar
  • 6 Amend KL, Turnbull B, Foskett N et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75: 1326-1332
    CrossrefPubMedGoogle Scholar
  • 7 Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev 2008; 8: 144-146
    CrossrefPubMedGoogle Scholar
  • 8 Calabrese LH, Molloy ES. Therapy: rituximab and PML risk-informed decisions needed!. Nat Rev Rheumatol 2009; 5: 528-529
    CrossrefPubMedGoogle Scholar
  • 9 Clifford DB, Ances B, Costello C et al. Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. Arch Neurol 2011; 68: 1156-1164
    CrossrefPubMedGoogle Scholar
  • 10 Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437
    CrossrefPubMedGoogle Scholar
  • 11 Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010; 33: 969-983
    CrossrefPubMedGoogle Scholar
  • 12 Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923
    CrossrefPubMedGoogle Scholar
  • 13 Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910
    CrossrefPubMedGoogle Scholar
  • 14 Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374
    CrossrefPubMedGoogle Scholar
  • 15 Langer-Gould A, Atlas SW, Green AJ et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381
    CrossrefPubMedGoogle Scholar
  • 16 Vermersch P, Kappos L, Gold R et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76: 1697-1704
    CrossrefPubMedGoogle Scholar
  • 17 Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008; 127: 280-285
    CrossrefPubMedGoogle Scholar
  • 18 Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 2010; 10: 791-809
    CrossrefPubMedGoogle Scholar
  • 19 Imamura H, Tanaka M, Kitagawa N et al. [Trial of rituximab in three patients with neuromyelitis optica]. Rinsho Shinkeigaku 2009; 49: 457-462
    CrossrefPubMedGoogle Scholar
  • 20 Pellkofer HL, Krumbholz M, Berthele A et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310-1315
    CrossrefPubMedGoogle Scholar
  • 21 Bedi GS, Brown AD, Delgado SR et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011; 17: 1225-1230
    CrossrefPubMedGoogle Scholar
  • 22 Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006; 66: 262-264
    CrossrefPubMedGoogle Scholar
  • 23 Twyman C, Berger JR. A giant MS plaque mimicking PML during natalizumab treatment. J Neurol Sci 2010; 291: 110-113
    CrossrefPubMedGoogle Scholar
  • 24 Koralnik IJ, Wuthrich C, Dang X et al. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57: 576-580
    CrossrefPubMedGoogle Scholar
  • 25 Wuthrich C, Dang X, Westmoreland S et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009; 65: 742-748
    CrossrefPubMedGoogle Scholar
  • 26 Brew BJ, Davies NW, Cinque P et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010; 6: 667-679
    CrossrefPubMedGoogle Scholar
  • 27 Phan-Ba R, Lommers E, Tshibanda L et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2011; 83: 224-226
    PubMedGoogle Scholar
  • 28 Boster A, Hreha S, Berger JR et al. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol 2009; 66: 593-599
    CrossrefPubMedGoogle Scholar
  • 29 Clifford DB, De Luca A, Simpson DM et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446
    CrossrefPubMedGoogle Scholar
  • 30 Shah R, Bag AK, Chapman PR et al. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 2010; 65: 431-439
    CrossrefPubMedGoogle Scholar
  • 31 Wang Y, Kirby JE, Qian Q. Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy. J Med Microbiol 2009; 58: 253-255
    CrossrefPubMedGoogle Scholar
  • 32 Viscidi RP, Khanna N, Tan CS et al. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011; 53: 711-715
    CrossrefPubMedGoogle Scholar
  • 33 Kuhle J, Gosert R, Buhler R et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011; 77: 2010-2016
    CrossrefPubMedGoogle Scholar
  • 34 Metz I, Radue EW, Oterino A et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 2011; 123: 235-245
    PubMedGoogle Scholar
  • 35 Rudick RA, O'Connor PW, Polman CH et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010; 68: 304-310
    CrossrefPubMedGoogle Scholar
  • 36 Zohren F, Toutzaris D, Klarner V et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111: 3893-3895
    CrossrefPubMedGoogle Scholar
  • 37 Warnke C, Smolianov V, Dehmel T et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 2011; 17: 151-156
    CrossrefPubMedGoogle Scholar
  • 38 Warnke C, Adams O, Hartung HP et al. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology]. Nervenarzt 2011; 82: 1314-1319
    CrossrefPubMedGoogle Scholar
  • 39 Ryschkewitsch CF, Jensen PN, Monaco MC et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010; 68: 384-391
    CrossrefPubMedGoogle Scholar
  • 40 Haghikia A, Perrech M, Pula B et al. Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One 2011; 6: e18506
    CrossrefPubMedGoogle Scholar
  • 41 Wyen C, Lehmann C, Fatkenheuer G et al. AIDS-related progressive multifocal leukoencephalopathy in the era of HAART: report of two cases and review of the literature. AIDS Patient Care STDS 2005; 19: 486-494
    CrossrefPubMedGoogle Scholar
  • 42 Khatri BO, Man S, Giovannoni G et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402-409
    CrossrefPubMedGoogle Scholar
  • 43 Wenning W, Haghikia A, Laubenberger J et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361: 1075-1080
    CrossrefPubMedGoogle Scholar
  • 44 Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53: 1840-1849
    CrossrefPubMedGoogle Scholar
  • 45 Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66: 255-258
    CrossrefPubMedGoogle Scholar
  • 46 Schroder A, Lee DH, Hellwig K et al. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010; 67: 1391-1394
    CrossrefPubMedGoogle Scholar
  • 47 Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011; 258: 1920-1928
    CrossrefPubMedGoogle Scholar
  • 48 Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol 2011; 24: 284-290
    CrossrefPubMedGoogle Scholar
  • 49 Tan K, Roda R, Ostrow L et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72: 1458-1464
    CrossrefPubMedGoogle Scholar
  • 50 Tan IL, McArthur JC, Clifford DB et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77: 1061-1067
    CrossrefPubMedGoogle Scholar
  • 51 Warnke C, Menge T, Hartung HP et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?. Arch Neurol 2010; 67: 923-930
    CrossrefPubMedGoogle Scholar